ClinicalTrials.gg
Sign In

Central Nervous System Neoplasms clinical trials

The registry lists 699 studies for Central Nervous System Neoplasms across more than 10 countries. 66 are recruiting or about to start. 461 of them are mainly about Central Nervous System Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 14 narrower conditions too, such as Brain Neoplasms: 3,572 studies, 819 open.

ClinicalTrials.gov finds 4,642 studies for Central Nervous System Neoplasms. How that becomes 699 here

This page counts the studies the registry files under Central Nervous System Neoplasms, and those it files under no condition that list Central Nervous System Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 4,642Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −2,724Filed under a narrower condition, counted on its own pageBrain Neoplasms 2,077 · Pituitary Neoplasms 168 · Meningioma 131 · Meningeal Carcinomatosis 102 · Diffuse Intrinsic Pontine Glioma 82 · Spinal Cord Neoplasms 70 · 8 more
  3. −4List Central Nervous System Neoplasms as a condition, but the registry did not file them under itMost often written as “Recurrent Primary Malignant Central Nervous System Neoplasm” (1), “Refractory Primary Malignant Central Nervous System Neoplasm” (1), and “Locally Advanced Primary Malignant Central Nervous System Neoplasm” (1). The registry filed them under other conditions only, most often Medulloblastoma (2) and Rhabdoid Tumor (2).
  4. −1,215Match it another way11 name it in the title, 1 in a keyword, and 1,203 by a synonym or other text the search reads.
  5. 699The count on this page3 of them list Central Nervous System Neoplasms in their own words; the registry filed them under no condition.

Get an email when these change. Save the Central Nervous System Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
441
Terminated
71
Recruiting
57
Status unknown
53
Withdrawn
35
Active, not recruiting
32

Phase

Phase 2
299
Phase 1
289
Phase 3
40
Early Phase 1
7
Phase 4
1

Where

United States
547
Canada
90
United Kingdom
52
Australia
46
France
45
Switzerland
41

Who runs them

National Cancer Institute (NCI) (51) · Children's Oncology Group (42) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (36) · Duke University (32) · Memorial Sloan Kettering Cancer Center (27) · European Organisation for Research and Treatment of Cancer - EORTC (23) · St. Jude Children's Research Hospital (20) · Children's Cancer and Leukaemia Group (18)

What is being tested here

Drugs under test in Central Nervous System Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Temozolomide29100
Etoposide1228
Irinotecan1023
Cabozantinib103
Nivolumab103
Etoposide phosphate103
ONC206102
Entrectinib102
Pembrolizumab102
Entinostat102

Drug classes tested here Alkylating agents 2 open · Tyrosine kinase inhibitors (TKIs) 2 open · Immune checkpoint inhibitors 2 open · Antimitotic agents 44 · Antimetabolites 26

Coming up

4phase 3 studies under way
29studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 57 Central Nervous System Neoplasms studies recruiting now, 35 (61%) set no upper age limit and 19 (33%) stop at 75 or younger. 35 (61%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 6 (11%) take healthy volunteers.

Recruiting studies that take each age, of 57
AgeWomenMen
1033 (58%)33 (58%)
1855 (96%)55 (96%)
3039 (68%)39 (68%)
4038 (67%)38 (67%)
5038 (67%)38 (67%)
6538 (67%)38 (67%)
7538 (67%)38 (67%)
8538 (67%)38 (67%)

Across all 699 studies, recruiting or not: 40% stop at 75 or younger and 36% at 65; 46% take children; <1% are for women only and 1% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Central Nervous System Neoplasms studies take

Of 54 phase 2 interventional studies under Central Nervous System Neoplasms, half reached primary completion within 58 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 146 mo37–73 · 52 studies—47 mo37–73 · 43 studies
Phase 1/258 mo48–85 · 35 studies——
Phase 258 mo44–77 · 54 studies—56 mo44–77 · 50 studies
Interventional, no phase127 mo43–175 · 18 studies——
Observational92 mo41–… · 39 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 699. Browse all 699 → or search them.